MIRA
INFORM REPORT
|
Report Date : |
27.12.2008 |
IDENTIFICATION DETAILS
|
Name : |
BIONGENE CO.,
LTD. |
|
|
|
|
Registered Office : |
10-1, Myeongnyundong 1-ga, Jongno-gu, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
26.09.1997 |
|
|
|
|
Com. Reg. No.: |
208-81-24696 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Manufacture of Other Food Additive Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
BIONGENE CO.,
LTD. (Korean Company
Name : “바이오앤진”) |
|
Registered Address |
10-1, Myeongnyundong 1-ga, Jongno-gu, |
|
Zip Code |
110-521 |
|
Tel |
+82-2-747-9004 |
|
Fax |
+82-2-747-0750 |
|
E-mail |
webmaster@biongene.com |
|
Website |
www.biongene.com |
|
Trading Address |
10-1, Myeongnyundong 1-ga, Jongno-gu, |
|
Tel |
+82-2-747-9004 |
|
Fax |
+82-2-747-0750 |
|
Other Address-R&D Center |
10-2, Myeongnyundong 1-ga, Jongno-gu, |
|
Tel |
+82-2-747-0700 |
|
Fax |
+82-2-747-0750 |
|
Other Address-Branch |
307 & 307-11, Songsan-ri,
Yanggam-myeon, Hwaseong-si, |
|
Type |
Import/Export |
|
Industry |
Manufacture of Other Food Additive Products |
|
Main Business |
Functional Food & Medicine Materials |
|
Sub
Business |
Manufacture of Finished Medicaments |
|
Established (mm/dd/yyyy) |
09/26/1997 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Formulas and products for nutritional
support(42231800) |
|
Sell |
Dietary supplements and nutritional therapy
products(51191900) |
|
Sell |
Chemicals including Bio Chemicals and Gas
Materials(12000000) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
CEO’s
|
Name |
Jung Soo-Ryun |
|
Address |
128, Cheongdam-dong, Gangnam-gu, |
|
Date of Birth |
03/31/1957 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Mr. Jung
Soo-Ryun has been graduated
from
Profiles
|
Capital |
1,816,500,000 KRW |
||||||||||||
|
Employees |
19 |
||||||||||||
|
Formation |
Co., Ltd by shares |
||||||||||||
|
Bank Details |
N/A |
||||||||||||
|
Corporate Registered No. |
110111-1466261 |
||||||||||||
|
Business Registered No. |
208-81-24696 |
||||||||||||
|
Permit & Licenses |
Awards 07/2000 KT Award for the Development of Biotechnological Production
Technology of Erythritol 12/2000 Industrial Cooperation Grand Prize for the Development of
Biotechnological Production Technology of Erythritol 01/2001 2000 Big Ten New Technologies Award for the Development of
Biotechnological Production Technology of Erythritol |
||||||||||||
|
Shareholder Position |
|
||||||||||||
|
Company History |
09/26/1997 Incorporated as Dong-Cheon
Consulting Company 05/10/2000 Changed company name to the
present name 05/10/2000 Increased the authorized shares
to 50,000,000 shares from 160,000 shares 05/20/2000 Increased capital to
1,600,000,000 KRW from 200,000,000 KRW 06/25/2000 Spin off the par value to 500
KRW from 5,000 KRW 07/22/2000 Increased capital to
1,650,000,000 KRW from 1,600,000,000 KRW 07/06/2002 Increased capital to
1,816,500,000 KRW from 1,650,000,000 KRW |
||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Jung Soo-Ryun |
Male |
Korean |
09/26/1997 |
|
Director |
Mr. |
Jung Ki-Ryun |
Male |
Korean |
09/26/1997 |
|
Director |
Mr. |
Kim Sang-Yong |
Male |
Korean |
05/10/2000 |
|
Auditor |
Mr. |
Hwang Kap-Sung |
Male |
Korean |
09/26/1997 |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
2004 |
|
|
340,000,000 |
The latest &
full financials are not available, and the Subject Company does not have any obligations
to release its financials to the public.
Financial Description
Unit: KRW
|
Authorized Capital |
2,500,000,000 |
|
Paid-Up Capital |
1,816,500,000 |
|
Total Issues Shares |
3,633,000 |
Products, Technologies, Services Description
|
Main Products & Services |
Thymidine for AIDS Medicine Intermediates Ubiquinone for Cardiac Disorders Medicine Teicoplanin for Antibiotics Acarbose Derivatives for Diabetes Medicine Lactulose for Intestinal Function Activator Peptide Antibiotics for Antibiotics Erythritol for Functional Sugar Alcohol Mannitol for Functional Sugar Alcohol |
Trade
Partners
|
Competitors |
DPM ENTERPRISE CO., LTD. 3RD FL., HONG-U BLDG., 834-34, YEOKSAM
1-DONG, GANGNAM-GU, TEL:+82-2-3474-8527 FAX:+82-2-3474-8528 NATURAL F
& P, INC. 319-11,
SONGDAE-RI, OCHANG-EUP, CHEONGWON-GUN, TEL:+82-43-211-1056 FAX:+82-43-217-1564 SECHANG INT`L CORP. A-1422, TEL:+82-2-2145-4883 FAX:+82-2-2145-4893 |
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
BOLAK CO.,
LTD.(134811-0004474) NAM YUNG COMMERICIAL CO.,
LTD.(110111-0014152) HWASAN COUNTRY CLUB CO.,
LTD.(134511-0007367) |
Sales by
Region (Activity &
Markets)
Not Available.
Court
Action
Not Available.
News
Clipping
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.47.89 |
|
|
1 |
Rs.70.84 |
|
Euro |
1 |
Rs.67.57 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)